DEEP MEDICINE ACQUISITION CORP. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K) - Marketscreener.com

Item 3.01 Notice of Delisting oregon Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On January 22, 2023, Deep Medicine Acquisition Corp., a Delaware corporation (the "Company") received a written announcement (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") indicating that, following the stockholder redemptions astatine the Company's past stockholder meeting, the Company is not successful compliance with Listing Rule 5450(b)(2), owed to the Company's nonaccomplishment to conscionable the minimum 1,100,000 publically held shares requirement for continued listing connected the Nasdaq Global Market. The Notice is lone a notification of deficiency, not of imminent delisting, and has nary existent effect on the listing oregon trading of the Company's securities connected the Nasdaq Global Market.

The Notice states that the Company has until March 9, 2023 to taxable a program to regain compliance with Listing Rule 5450(b)(2). The Company is exploring all options to regain compliance with Listing Rule 5450(b)(2).The Company intends to submit a program to regain compliance with Listing Rule 5450(b)(2) wrong the required timeframe. If Nasdaq accepts the Company's plan, Nasdaq whitethorn assistance the Company an hold of up to 180 calendar days from the day of the Notice to evidence compliance with Listing Rule 5450(b)(2). If Nasdaq does not judge the Company's plan, the Company volition person the accidental to entreaty the determination in front of a Nasdaq Hearings Panel.

Certain statements successful this study that are not based connected humanities information are "forward-looking statements" wrong the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, arsenic amended, and Section 21E of the Securities Exchange Act of 1934, arsenic amended (which Sections were adopted arsenic portion of the Private Securities Litigation Reform Act of 1995). While absorption has based any forward-looking statements contained herein connected its existent expectations, the information connected which specified expectations were based whitethorn change. These forward-looking statements trust connected a fig of assumptions concerning future events and are taxable to a fig of risks, uncertainties, and different factors, many of which are extracurricular of the Company's control, that could origin actual results to materially disagree from specified statements. Accordingly, investors should not spot immoderate reliance connected forward-looking statements arsenic a prediction of actual results. The Company disclaims immoderate volition to, and undertake nary work to, update oregon revise immoderate forward-looking statement.

© Edgar Online, root Glimpses